– USA, DE – Incyte Corporation (Nasdaq: INCY) today announced the appointment of Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin Pharmaceutical Inc., and Paul J. Clancy, Executive Vice President, Finance and Chief Financial Officer of Biogen Idec Inc., as new Directors. The appointments are effective January 20, 2015.
“The Incyte board welcomes Jean-Jacques and Paul as their extensive and relevant experience in building successful biotechnology companies promises to be of great value to Incyte,” said Richard DeSchutter, Chairman of the Incyte Board of Directors.
“The addition of these two highly qualified individuals to our board is testament to Incyte’s continued growth and success,” added Hervé Hoppenot, Incyte’s President and CEO. “I’m confident the management team will benefit from their broad industry experience and shared commitment to building significant and sustainable shareholder value. We look forward to working with them.”
Jean-Jacques Bienaimé
Mr. Bienaimé has served as CEO and a Board member of BioMarin since May 2005. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. From 1998 to 2002, he was Chairman, President and Chief Executive Officer of SangStat Medical Corporation, another biotechnology company. Prior to joining SangStat, Mr. Bienaimé held various management positions from 1992 to 1998 with Rhône-Poulenc Rorer Pharmaceuticals (now known as Sanofi-Aventis).
Mr. Bienaimé currently serves on the board of Vital Therapies, Inc., a biotechnology company, as well as the Biotechnology Industry Organization(BIO). He received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.
Paul J. Clancy
Paul J. Clancy is Executive Vice President, Finance and Chief Financial Officer of Biogen Idec and has served in these positions since August 2007. From 2001 to 2007, Mr. Clancy held several senior executive positions with Biogen Idec and its predecessor Biogen, Inc., including Vice President of Business Planning, Portfolio Management and U.S. Marketing, and Senior Vice President of Finance. Prior to that, he spent 13 years at PepsiCo serving in a range of financial and general management positions.
Mr. Clancy serves on the board of directors of Agios Pharmaceuticals, Inc., a biopharmaceutical company. He received his B.S. in Finance from Babson College and M.B.A. from Columbia University.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily for oncology.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
